Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Noxopharm Ltd V.NOX


Primary Symbol: NOXOF

Noxopharm Limited is a biotech company. It is engaged in discovering and developing novel treatments for cancer and inflammation, including a pioneering technology to enhance messenger ribonucleic acid (mRNA) vaccines. It utilizes specialist in-house capabilities and partnerships with researchers to build a pipeline of new proprietary drugs based on two technology platforms: Chroma (oncology) and Sofra (inflammation, autoimmunity, and mRNA vaccine enhancement). Chroma is a technology platform focused on the development of multiple drug candidates, primarily for cancer treatment. The Sofra technology platform has a pipeline of proprietary drugs based on oligonucleotides, the building blocks of deoxyribonucleic acid (DNA), with a focus on mRNA vaccines and the treatment of autoimmune and inflammatory diseases. SOF-VAC has applications in the treatment of excessive inflammatory responses associated with specialized inflammatory receptors in the body known as Toll-like receptor 7.


OTCPK:NOXOF - Post by User

Comment by MrMonkon Jul 03, 2013 5:17pm
60 Views
Post# 21587718

RE:New estimate not exciting

RE:New estimate not excitingThe last update was by SGS (Aurizon's pick) and this one was done by MDA (Niogold's guys - they also did the first resource estimate in 2010).  The number of ounces in Phase II didn't go up a great deal - perhaps a few hundred thousand - however because MDA revised the Phase I resource (different parameters and grade cut-offs), the numbers are different from what SGS reported.  There should be much more confidence in the MDA model and this should benefit NOX and its shareholders longer-term.

The deposit at Marban (still a very good deposit) and the others (Norlartic, Kierens, etc.) can all be mined at a single mill centrally located.  The property requires more drilling and whether Hecla/Aurizon continues or NOX goes it alone (or it secures a new partner), development drilling will continue.

By the way, Simon Ridgway is no slouch.  He is a very successful mine developer who helped NOX to negotiate the original deal with ARZ.  Simon brings even more credibility to NOX and can open doors with his significant mining contacts.

Slow and steady will win this race...

- MM
<< Previous
Bullboard Posts
Next >>